Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692705 | 0.80 | — | — | |
| SCHEMBL4881159 | 0.80 | TSHR (0.33) | TSHRLMNATHRB | |
| SCHEMBL3151320 | 0.79 | CYP3A4 (0.33) | TSHRTHRB | |
| SCHEMBL509694 | 0.76 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL20607569 | 0.76 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL29082891 | 0.76 | TSHR (0.40) | TSHRLMNATHRB | |
| SCHEMBL135552 | 0.75 | TSHR (0.46) | TSHRLMNATHRB | |
| SCHEMBL28438742 | 0.75 | TSHR (0.46) | TSHRLMNATHRB | |
| SCHEMBL7295022 | 0.74 | CYP3A4 (0.31) | TSHR | |
| SCHEMBL1680269 | 0.74 | TSHR (0.42) | TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4688768-A1 | NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY | Novalix (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025244963-A1 | ECTEINASCIDIN DERIVATIVES AND METHODS OF USE THEREOF AS ANTITUMOR AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-26 | — | — | US | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| US-20250170126-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-05-29 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-5723488-A | Antiparasitic agents | PFIZER INC. (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997043260-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0745089-A1 | ANTIPARASITIC AGENTS | Pfizer Limited (GB) | 1996-12-04 | — | — | EP | disclosed |
| EP-0677523-A1 | 3-(substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995022552-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 1995-08-24 | — | — | WO | disclosed |
| US-5258509-A | Catalytic detherification and alkylation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-11-02 | — | — | US | disclosed |
| US-5128336-A | Antibiotics | ELI LILLY AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0430037-A2 | Process for producing 2-carbon-substituted carbapenem derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-06-05 | — | — | EP | disclosed |
| EP-0334590-A2 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4855418-A | Process for production of ceophalosporins | ELI LILLY AND COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109709-A1 | 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | TSHR 1646/4885LMNA 1620/4885THRB 1414/4885 |
| US-20250170126-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | TSHR 3094/4885LMNA 3931/4885THRB 1333/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | TSHR 4232/4885LMNA 1086/4885THRB 4233/4885 |
| US-20250206744-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | IL17A, IL23R, IL15 | TSHR 791/4885LMNA 4729/4885THRB 1346/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | TSHR 3422/4885LMNA 1841/4885THRB 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.